| Amantadine therapy for chronic hepatitis C. | |
| | |
MedLine Citation:
|
PMID: 15209605 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Although treatment of hepatitis C has improved, up to 50% do not respond to standard therapy with interferon regimes or cannot tolerate the treatment due to side effects. The purpose of the present investigation was to evaluate the safety and effectiveness of the antiviral drug amantadine for the treatment of hepatitis C in those who had either previously failed interferon therapy or were not candidates for interferon. DESIGN: A prospective double-blind randomized placebo-controlled trial. SETTING: Outpatient research clinic of a teaching hospital. PATIENTS/PARTICIPANTS: One hundred fifty-two patients with confirmed hepatitis C with abnormal liver enzymes, detectable hepatitis C RNA in the blood, and abnormal liver histology by biopsy were randomized to receive treatment or placebo. MEASUREMENTS AND MAIN RESULTS: Patients received either amantadine 100 mg twice daily by mouth or placebo for 6 months. After 6 months, placebo-treated patients were crossed over and treated with amantadine for 6 months and amantadine-treated subjects received 6 additional months of therapy. Amantadine therapy resulted in a significant decline in serum alanine aminotransferase compared to placebo (P =.03). Nine percent cleared the virus at the end of therapy and 6.8% had a sustained virologic response 6 months after discontinuation of amantadine, but this was not statistically significant. Side effects were minimal, and the social quality of life survey improved with 12 months of amantadine (P =.02). CONCLUSIONS: Oral amantadine may provide a safe alternative treatment for those patients who are intolerant or unresponsive to interferon. |
| | |
Authors:
|
Jill P Smith; Thomas R Riley; Attila Devenyi; Sandra I Bingaman; Allen Kunselman |
Related Documents
:
|
23609045 - Safety and efficacy of low molecular weight dextran (dextran 40) in head and neck free ... 15916455 - Subcutaneous recombinant interferon-beta-1a (rebif): a review of its use in relapsing-r... 10846595 - Persisting long-term benefit of genotype-guided treatment for hiv-infected patients fai... 11039675 - Effective and safe interferon treatment for japanese patients with chronic myelogenous ... 20014995 - Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglan... 22999755 - Long-term results of percutaneous biliary balloon dilation treatment for benign hepatic... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of general internal medicine Volume: 19 ISSN: 0884-8734 ISO Abbreviation: J Gen Intern Med Publication Date: 2004 Jun |
Date Detail:
|
Created Date: 2004-06-22 Completed Date: 2005-05-26 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 8605834 Medline TA: J Gen Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: 662-8 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Pennsylvania State College of Medicine, The Milton S Hershey Medical Center, Hershey, PA 17033-0850, USA. jsmith2@psu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Alanine Transaminase / blood Amantadine / therapeutic use* Antiviral Agents / therapeutic use* Child Double-Blind Method Female Hepacivirus / isolation & purification* Hepatitis C, Chronic / blood, drug therapy*, virology Humans Infant Male Patient Dropouts Quality of Life RNA, Viral / analysis Sex Factors Time Factors |
| Grant Support | |
ID/Acronym/Agency:
|
R01 AI41613/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/RNA, Viral; 768-94-5/Amantadine; EC 2.6.1.2/Alanine Transaminase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Do neurologists and primary care physicians agree on the extent of specialty involvement of patients...
Next Document: Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clini...